NEWS

Medtronic Receives CE Mark Approval for Radial Artery Access Portfolio

Portfolio Features First Catheter Specifically Designed to Allow Neurointerventionalists Radial Artery Access, Delivers Advantages to Patients Treated for Stroke, Brain Aneurysms, Other Neurovascular Conditions Now Available in the United Kingdom, Italy, Spain, Germany and France

Sensome begins human trial for its AI-powered stroke guidewire

Paris, France - September 13th, 2021 - Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that Gold Coast University Hospital (GCUH) in Australia enrolled the first patients in the Company’s CLOT OUT first-in-human study evaluating safety and performance of the Clotild® Smart Guidewire System in large-vessel acute ischemic stroke patients.

Wallaby Medical partners with Brainomix to bring the most comprehensive...

SHANGHAI, CHINA – August 26, 2021 -  Wallaby Medical (“Wallaby”), a rapidly growing medical device company focused on developing and commercializing medical device products for treating stroke, and Brainomix Limited (“Brainomix”), a UK-headquartered company that specializes in the creation of AI-powered imaging biomarkers and software solutions that enable precision medicine for better treatment decisions, announced the signing of a new distribution agreement. As part of the agreement, Wallaby will distribute Brainomix’s e-Stroke software to stroke centres across Greater China.

Following its acceptance into Frontiers in Neurology, phenox is pleased...

In  the paper by Serna Candel et. al* , the outcomes of pRESET 4x20 were examined against the outcomes of cases where pRESET 5x40 was the stentriever of choice. The results speak for themselves and it is clear that the theory of longer stentrievers leading to better patient outcomes is proven here once again.

Philips announces first patient enrolled in the WE-TRUST global multicen...

Amsterdam, the Netherlands –  Royal Philips  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the first patient has been enrolled in the WE-TRUST study at Vall d’Hebron University Hospital, Barcelona, Spain, marking the official start of this major multicenter randomized controlled trial to assess if the  Direct to Angio Suite  workflow can improve outcomes for early time-window stroke patients (less than six hours after stroke onset).

Philips accelerates stroke diagnosis and treatment with expanded integra...

Amsterdam, the Netherlands –  Royal Philips  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a strategic partnership agreement with  NICO.LAB , a MedTech stroke care company. Together with the recently expanded stroke capabilities of Philips Image Guided Therapy System – Azurion – this new partnership significantly advances Philips’ commitment to improving outcomes for people who suffer a stroke. Philips is connecting information, technologies and people across the stroke care pathway, enabling care teams to work quickly and act decisively - a key factor in providing the best patient treatment.

Sensome receives FDA "Breakthrough device designation" for its AI-powere...

Paris, France, June 21st, 2021, – Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that it has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its Clotild® Smart Guidewire System designed to improve the treatment of ischemic stroke patients.

Vesalio Secures Class A Funding

Nashville, TN, June 2, 2021 Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business. This round, led by Solas BioVentures, included participation from both new and existing investors.

Vesalio Initiates FDA IDE Stroke Study

Nashville, TN, May 11, 2021 Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022.

Perflow Medical Expands Product Portfolio with First Clinical Use of the...

NETANYA, Israel, April 29, 2021 - Perflow Medical, a private, Israeli-based innovator for neurovascular treatments, today announced the first successful clinical use of the Stream™17 Dynamic Neuro-Thrombectomy Net, a lower profile device designed for more tortuous anatomy, to effectively treat hemorrhagic and ischemic stroke patients.